KLDC2 Antibody (C-term) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q9Y2U9 |
---|
Gene ID | 23588 |
---|---|
Other Names | Kelch domain-containing protein 2, Hepatocellular carcinoma-associated antigen 33, Host cell factor homolog LCP, Host cell factor-like protein 1, HCLP-1, KLHDC2, HCA33 |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | KLHDC2 {ECO:0000303|PubMed:16964437, ECO:0000312|HGNC:HGNC:20231} |
---|---|
Function | Substrate-recognition component of a Cul2-RING (CRL2) E3 ubiquitin-protein ligase complex of the DesCEND (destruction via C-end degrons) pathway, which recognizes a C-degron located at the extreme C terminus of target proteins, leading to their ubiquitination and degradation (PubMed:29779948, PubMed:29775578, PubMed:30526872). The C- degron recognized by the DesCEND pathway is usually a motif of less than ten residues and can be present in full-length proteins, truncated proteins or proteolytically cleaved forms (PubMed:29779948, PubMed:29775578, PubMed:30526872). The CRL2(KLHDC2) complex specifically recognizes proteins with a diglycine (Gly-Gly) at the C- terminus, leading to their ubiquitination and degradation (PubMed:29779948, PubMed:29775578, PubMed:30526872). The CRL2(KLHDC2) complex mediates ubiquitination and degradation of truncated SELENOK and SELENOS selenoproteins produced by failed UGA/Sec decoding, which end with a diglycine (PubMed:26138980, PubMed:30526872). The CRL2(KLHDC2) complex also recognizes proteolytically cleaved proteins ending with Gly-Gly, such as the N-terminal fragment of USP1, leading to their degradation (PubMed:29775578, PubMed:30526872). May also act as an indirect repressor of CREB3-mediated transcription by interfering with CREB3-DNA-binding (PubMed:11384994). |
Cellular Location | Nucleus |
Tissue Location | Widely expressed, with high levels in skeletal muscle, heart, pancreas and liver (PubMed:11384994, PubMed:16964437) Undetectable in peripheral blood leukocytes (PubMed:16964437) |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
KLDC2 represses CREB3-mediated transcription by interfering with CREB3-DNA binding.
References
Chin, K.T., et al. Mol. Cell. Biochem. 296 (1-2), 109-119 (2007) Ewing, R.M., et al. Mol. Syst. Biol. 3, 89 (2007)Wang, Y., et al. J. Immunol. 169(2):1102-1109(2002)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.